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Abstract 64 
In vitro susceptibility of 933 Candida isolates, from 16 French hospitals, to micafungin was 65 
determined using the Etest® in each center. All isolates were centralized for determination of 66 
minimum inhibitory concentrations (MICs) by the EUCAST reference method. Overall 67 
essential agreement between the two tests was 98.5% at ± 2 log2 dilutions and 90.2% at ± 1 68 
log2 dilutions. Categorical agreement was 98.2%. The Etest® is a valuable alternative to 69 
EUCAST for the routine determination of micafungin MICs in medical mycology laboratories. 70 
71 
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The echinocandin antifungal drug micafungin is highly effective in vitro against most 72 
Candida species (1-3). Micafungin is now widely used for prophylaxis and treatment of 73 
invasive candidiasis (IC) (4, 5). During the last decade, acquired resistance of various 74 
Candida species to echinocandins has emerged worldwide, including France, and may 75 
become an important issue in the therapeutic management of IC (6-10).  76 
In vitro antifungal susceptibility testing is currently recommended to detect resistance in 77 
Candida species and to guide antifungal treatment (6, 11). Microdilution broth methods such 78 
as EUCAST and CLSI are the reference methods for antifungal susceptibility testing. 79 
Nevertheless, because these reference methods are labor intensive and time-consuming, most 80 
clinical microbiology laboratories use commercial methods, such as the Etest®, for routine 81 
determination of minimum inhibitory concentrations (MICs). It is therefore essential to 82 
evaluate these commercial tests and to determine their ability to give MIC values that agree 83 
with those from the reference methods. 84 
With this aim, a prospective, multicenter French study was performed to compare the 85 
EUCAST and Etest® methods for micafungin susceptibility testing of a large panel of clinical 86 
isolates of different Candida species. Sixteen centers (six in Paris area and 10 across France) 87 
participated in the study. Over a 2-month period, each center was asked to test 64 Candida 88 
isolates, from any clinical sample, of the following species: 10 isolates of each of the six most 89 
common pathogenic species (C. albicans, C. glabrata, C. tropicalis, C. parapsilosis, C. kefyr 90 
and C. krusei) and four isolates belonging to other Candida species. Species identification 91 
was performed in each center according to the currently recommended phenotypic methods 92 
(12). Micafungin susceptibility testing was performed using the Etest® (Biomérieux, Marcy 93 
l’Etoile, France), according to the manufacturer’s instructions. Candida isolates were then 94 
centralized in a single center for MIC determination by the EUCAST reference method (13). 95 
C. krusei ATCC 6258 and C. parapsilosis ATCC 22019 were included as quality control 96 
6 
 
strains (14). For comparison purposes, Etest® MICs were increased to the next higher 97 
corresponding EUCAST concentration (15). Resistance was based on EUCAST clinical 98 
breakpoints.  When clinical breakpoints were not available (i.e. for C. krusei and C. 99 
tropicalis), ECOFFs were used to categorize isolates as non-wild-type (16). The same 100 
ECOFFs (defined by EUCAST) were used for analyzing results of Etest® as specific ECOFFs 101 
have not been determined yet. C.albicans, C. glabrata, and C. parapsilosis isolates were 102 
considered susceptible / resistant to micafungin when MICs were ≤0.016 / >0.016 µg/ml, 103 
≤0.03 / >0.03 µg/ml, and ≤0.002 / >2 µg/ml, respectively. C. krusei and C. tropicalis isolates 104 
were considered wild-type / non-wild-type to micafungin when MICs were ≤0.25 / >0.25 105 
µg/ml and ≤0.06 / >0.06 µg/ml, respectively. MIC results obtained by the two methods were 106 
considered to be in essential agreement when they were within   ± 2 log2 dilutions. Agreement 107 
at ± 1 log2 dilution was also calculated. Categorical agreement was defined as the percentage 108 
of isolates classified in the same category (i.e. susceptible, intermediate, and resistant or wild-109 
type and non-wild-type) by both techniques (15). Discrepancies (very major, major, and 110 
minor errors) were defined as described previously (15). 111 
Results from antifungal susceptibility testing were available for 933 Candida isolates, 112 
including 878 isolates of the six most medically important Candida species and 55 other 113 
Candida species. Table 1 shows the micafungin MICs for the 933 isolates determined by the 114 
EUCAST reference method. Micafungin MICs for C. parapsilosis isolates (modal MIC of 1 115 
µg/ml) were several dilutions higher than for the other common species (modal MIC of 0.015 116 
µg/ml for C. albicans, C. tropicalis, and C. glabrata and 0.03 and 0.06 µg/ml for C. kefyr and 117 
C. krusei, respectively). MICs for rare species were similar than those of the common species 118 
except for C. colliculosa and some isolates of C. guilliermondii and C. famata.  According to 119 
the current clinical breakpoints (16), the micafungin resistance rate was <2% for C. albicans 120 
and C. parapsilosis, and 3.9% for C. glabrata. Based on ECOFFs, the non-wild-type rate was 121 
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0.7% for C. tropicalis and 0% for C. krusei. The overall essential agreement between 122 
EUCAST and Etest® results was high (98.5% at ± 2 log2 dilutions and 90.2% at ± 1 log2 123 
dilution) (Figure 1) with minor differences between species (Table 2). The lowest essential 124 
agreement (96.7% at ± 2 log2 dilutions) was observed for C. parapsilosis. An overall 125 
categorical agreement of 98.2% was observed for the 742 isolates belonging to the five 126 
species for which clinical breakpoints or ECOFFs are available (Table 3). The highest (100%) 127 
and lowest (96.7%) categorical agreements were found for C. krusei and C. glabrata, 128 
respectively. Major errors were observed in six cases (three C. albicans, two C. tropicalis, and 129 
one C. glabrata) and very major errors in six cases (two C. albicans and four C. glabrata). 130 
These 12 discrepancies were observed for strains isolated and tested in eight different centers. 131 
The Etest® has been used in several studies for micafungin susceptibility testing of Candida 132 
spp. (17-22), but only a few comparative studies with a reference method have been 133 
performed (17, 20-22). In one of these previous studies, Marcos-Zambrano et al. (21) tested 134 
160 yeast isolates with both the Etest® and EUCAST methods and reported an essential 135 
agreement of 90.3% at ± 2 log2 dilutions (85.8% at ± 1 log2 dilution) and a categorical 136 
agreement of >90%. Similarly, in another study, a comparison between Etest® and CLSI 137 
methods showed an overall essential agreement of 94.7% and a categorical agreement of 138 
97.2% (20). The ability of the Etest® to detect micafungin resistance, for most of the species, 139 
has also been demonstrated previously by testing FKS mutant isolates (17, 21, 22). We 140 
enrolled 16 centers and demonstrated that under real-life conditions the Etest® gave very 141 
similar micafungin susceptibility results to the EUCAST reference method. 142 
Altogether, our results show that the Etest® is a valuable and reliable method to routinely test 143 
the in vitro susceptibility of clinical Candida isolates to micafungin. In vitro micafungin 144 
resistance among the main Candida species isolated from clinical samples remains 145 
uncommon in France. 146 
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Table 1: Distribution of micafungin MICs (µg/ml) for different Candida species (n=933) 272 
determined by the EUCAST broth microdilution method 273 
Species (number of 
isolates) 
Number of isolates with an MIC (µg/ml) of % R/non 
WT*        
0.015 0.03 0.06 0.125 0.25 0.5 1 2 4  
C. albicans (159) 157 1 1             1.3 
C. glabrata (152) 137 9 4     1 1     3.9 
C. parapsilosis (152)       1 5 13 79 52 2 1.3 
C. tropicalis (152) 97 48 6       1     0.7 
C. kefyr (136) 7 67 49 13           ND 
C. krusei (127) 3 1 59 56 8         0 
C. lusitaniae (23)   5 16 2           ND 
Other Candida spp.# (32) 11  6  3 1  1 5 5     ND 
All isolates (933) 412 137 138 73 14 19 86 52 2  
 274 
ND: not determined. 275 
* Resistance (R) or non-wild-type (WT) was defined based on EUCAST clinical breakpoints 276 
or ECOFFs when clinical breakpoints were not available. 277 
# C. guilliermondii (9), C. norvegensis (5), C. inconspicua (5), C. famata (3), C. pelliculosa 278 
(2), C. lambica (2), C. sphaerica (1),  C. ciferrii (1),  C. catenulata (1), C. utilis (1), C. 279 
colliculosa (1), C. nivariensis (1). 280 
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Table 2 In vitro susceptibilities of the 933 Candida isolates to micafungin as determined by the Etest® method and EUCAST broth 281 
microdilution method 282 
 283 
Species (number of isolates) 
Etest® MIC (µg/ml) EUCAST MIC (µg/ml) 
Essential agreement#Range MIC50 MIC90 GM Range MIC50 MIC90 GM 
C. albicans (159) ≤0.015 - 0.06 0.015 0.015 0.016 ≤0.015 - 0.06 0.015 0.015 0.016 100 
C. glabrata (152) ≤0.015 - 0.125 0.015 0.015 0.016 ≤0.015 - 1 0.015 0.015 0.018 98.7 
C. parapsilosis (152) 0.06 - 4 0.5 2 0.63 ≤0.125 - 4 1 2 1.15 96.7 
C. tropicalis (152) ≤0.015 - 0.5 0.015 0.03 0.019 ≤0.015 - 1 0.015 0.03 0.021 99.3 
C. kefyr (136) ≤0.015 - 0.25 0.03 0.125 0.036 ≤ 0.015 - 0.125 0.03 0.06 0.044 97.8 
C. krusei (127) ≤0.015 - 0.25 0.125 0.125 0.084 ≤0.015 - 0.25 0.125 0.125 0.089 98.4 
Other Candida spp.* (55) ≤0.015 - 1 0.03 0.25 0.057 ≤0.015 - 1 0.06 0.5 0.068 98.2 
Total number (933) ≤0.015 - 4 0.03 0.5 0.046 ≤0.015 - 4 0.03 1 0.054 98.5 
*C. lusitaniae (23), C. guilliermondii (9), C. norvegensis (5), C. inconspicua (5), C. famata (3), C. pelliculosa (2), C. lambica (2), C. sphaerica 284 
(1),  C. ciferrii (1),  C. catenulata (1), C. utilis (1), C. colliculosa (1), C. nivariensis (1). 285 
#± 2 log2 dilutions.  286 
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Table 3 Categorical agreement between the EUCAST and Etest® methods for in vitro susceptibility testing of the major pathogenic 287 
Candida species to micafungin* 288 
 289 
Species (number of 
isolates) 
Categorical agreement Minor error Major error Very major error 
n % n % n % n % 
C. albicans (159) 154 96.9  -  - 3 1.9 2 1.2 
C. glabrata (152) 147 96.7  -  - 1 0.7 4 2.6 
C. parapsilosis (152) 151 99.3 1 0.7 0 0 0 0 
C. tropicalis (152) 150 98.7  -  - 2 1.3 0 0 
C. krusei (127) 127 100  -  - 0 0 0 0 
All isolates (742) 729 98.2 1 0.1 6 0.8 6 0.8 
 290 
* For both techniques, categorization of isolates as resistant or non-wild-type was defined based on EUCAST endpoints (clinical breakpoints or 291 
ECOFFs when clinical breakpoints were not available) 292 
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Figure 1 Correlation between EUCAST and Etest® methods for in vitro susceptibility testing of 933 Candida isolates to micafungin 293 
 294 
 295 

